Effect of Previous Differential Treatments on the Efficacy after Switching to Flumatinib in Patients with Chronic Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.05.002
- Author:
Xiao-Han WANG
1
;
Jing-Ya SUN
1
;
Ling-Ling YIN
1
;
Ting-Ting QIU
1
;
De-Peng LI
1
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical Universiy, Xuzhou 221000, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
chronic myeloid leukemia;
flumatinib;
tyrosine kinase inhibitors;
efficacy
- MeSH:
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Retrospective Studies;
Imatinib Mesylate/therapeutic use*;
Dasatinib/therapeutic use*;
Treatment Outcome;
Pyrimidines/therapeutic use*;
Female;
Male;
Protein Kinase Inhibitors/therapeutic use*;
Middle Aged;
Antineoplastic Agents/therapeutic use*
- From:
Journal of Experimental Hematology
2025;33(5):1248-1253
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of different previous treatments on the efficacy of flumatinib in patients with chronic myeloid leukemia (CML).
METHODS:The clinical data of 69 patients with CML treated with flumatinib in the Affiliated Hospital of Xuzhou Medical University from 2019 to 2024 were retrospectively analyzed. The patients were divided into a first-line flumatinib group and a first-line non-flumatinib group according to whether flumatinib was used as first-line treatment. The molecular response (MR) at 3, 6 and 12 months of treatment was compared between the two groups to evaluate the early efficacy. The first-line non-flumatinib group was further divided into imatinib group, nilotinib group, and dasatinib group according to the previous first-line drugs used. The efficacy data of these three groups at 3, 6 and 12 months after switching to flumatinib were collected, and the MR was evaluated to compare efficacy differences.
RESULTS:The rate of early molecular response (EMR) in the first-line flumatinib group was significantly higher than that in the first-line non-flumatinib group (P < 0.05). At 6 months and 12 months of treatment, the proportion of patients achieving MR 4.5 in the first-line flumatinib group was significantly higher than that in the first-line non-flumatinib group (P < 0.05). Compared with the imatinib and nilotinib groups, the previous dasatinib group showed a significantly higher proportion of patients achieving MR 5.0 at 3, 6, and 12 months after switching to flumatinib (P < 0.05).
CONCLUSION:Compared with the previous treatment with other tyrosine kinase inhibitors (TKIs), initial use of flumatinib at diagnosis enable patients to achieve deeper molecular remission more rapidly. Compared with previous use of imatinib or nilotinib, previous use of dasatinib is associated with deeper molecular remission after switching to flumatinib.
